Condition (MeSH)
Puberty, Precocious
ClinicalTrials.gov lists 73 trials for Puberty, Precocious or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
73 of the 73 trials are tagged with Puberty, Precocious itself; the rest are tagged with a narrower condition beneath it.
When did Puberty, Precocious trials start? (26)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 1 |
| 2024 | 7 |
| 2023 | 7 |
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 26 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Puberty, Precocious trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 16 |
| Phase 4 | 9 |
| Not applicable | 13 |
| Observational | 27 |
How many Puberty, Precocious trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 14 |
| Active, not recruiting | 2 |
| Completed | 39 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Puberty, Precocious trials? (12)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ipsen | 4 |
| Takeda | 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 3 |
| Abbott | 2 |
| AstraZeneca | 2 |
Showing 5 of 12 sponsors.
Which drugs are being tested for Puberty, Precocious? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Triptorelin Pamoate | 4 |
| Testolactone | 2 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Lupron / Leuprolide acetate | 9 |
| Triptorelin SR | 3 |
| GnRH Agonist | 2 |
| LEUPRORELIN ACETATE | 2 |
| NO GnRHa | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Puberty, Precocious trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 8 | 4 |
| Aggression | 2 | 1 |
| Bronchitis | 2 | 2 |
| Depression | 2 | 2 |
| Foot fracture | 2 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Puberty, Precocious? (89)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Precocious Puberty in Children with Neurofibromatosis Type 1. | The Journal of pediatrics | 2025 | Yes |
| Efficacy and safety of leuprorelin 3-month depot (11.25 mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study. | Journal of pediatric endocrinology & metabolism : JPEM | 2024 | Yes |
| A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty. | Advances in therapy | 2024 | Yes |
| [Expert consensus on the diagnosis and treatment of central precocious puberty(2022)]. | Zhonghua er ke za zhi = Chinese journal of pediatrics | 2023 | Yes |
| Efficacy and safety of a 4-year combination therapy of growth hormone and gonadotropin-releasing hormone analogue in pubertal girls with short predicted adult height. | Frontiers in endocrinology | 2023 | Yes |
Showing 5 of 89 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.